Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease
CompanyDrug

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877; SHA: 688180) announced a dual regulatory advance for its PD‑1 inhibitor toripalimab (brand name: Loqtorzi, product code: JS001): the indication for locally advanced…

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

HutchMed's Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

HutchMed’s Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Merck's PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China
CompanyDrug

Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China

Wuhan YZY Biopharma's M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
CompanyDrug

Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024

Immunofoco's IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer
CompanyDrug

Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting
CompanyDrug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
CompanyDrug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

CSPC Pharmaceutical Group's SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review
CompanyDrug

CSPC Pharmaceutical Group’s SYHX2011 for Metastatic Breast Cancer Accepted for NMPA Review

AstraZeneca's Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer
CompanyDrug

AstraZeneca’s Imfinzi Receives FDA Priority Review for Muscle-Invasive Bladder Cancer

AstraZeneca's Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
CompanyDrug

AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC

Show More